Advertisement

Advertisement

Geriatric Oncology
Symptom Management

Effect of Geriatric Assessment–Driven Intervention on Incidence of Severe Chemotherapy-Related Toxicity in Older Patients With Cancer

In a single-center study reported in JAMA Oncology, Daneng Li, MD, and colleagues found that a geriatric assessment–driven intervention (GAIN) was associated with a reduced incidence of grade ≥ 3 adverse events and a higher frequency of completion of advance directives vs standard of care among...

Hematologic Malignancies
Symptom Management

Ruxolitinib Granted FDA Approval for Chronic Graft-vs-Host Disease

On September 22, the U.S. Food and Drug Administration approved ruxolitinib (Jakafi), a JAK inhibitor, for the treatment of chronic graft-vs-host disease (GVHD) after failure of one or two lines of systemic therapy in adult and pediatric patients aged 12 years and older. REACH3 Efficacy was...

Immunotherapy
Symptom Management

Technology-Enabled Monitoring of Adverse Reactions to Immune Checkpoint Inhibitors

In an interim analysis of a single-institution study reported in JAMA Network Open, Pavlos Msaouel, MD, PhD, and colleagues found that the use of a mobile device application for patient reporting of adverse reactions to immune checkpoint inhibition was feasible. It permitted identification of...

Breast Cancer
Symptom Management

Pharmacologic Cardioprotection in Women With Nonmetastatic Breast Cancer Receiving Anthracycline-Based Chemotherapy

In an interim analysis of the Italian phase III SAFE trial reported in JAMA Oncology, Livi et al found that a cardioprotective strategy using ramipril and/or bisoprolol reduced the risk of myocardial dysfunction in women with nonmetastatic breast cancer receiving anthracycline-based chemotherapy....

Hematologic Malignancies
Symptom Management

Belumosudil for Chronic Graft-vs-Host Disease

On July 16, 2021, belumosudil, an inhibitor of Rho-associated coiled-coil kinase 2, was approved for the treatment of adult and pediatric patients 12 years and older with chronic graft-vs-host disease after the failure of at least two prior lines of systemic therapy.1 Supporting Efficacy Data...

Hematologic Malignancies
Head and Neck Cancer
Gynecologic Cancers
Immunotherapy
Symptom Management

FDA Pipeline: Reviews for Agents in Acute Graft-vs-Host Disease, Nasopharyngeal and Ovarian Cancers

Recently, the U.S. Food and Drug Administration (FDA) granted Priority Review to an agent for the prevention of acute graft-vs-host disease; Breakthrough Therapy designation to an anti–PD-1 monoclonal antibody for the treatment of metastatic nasopharyngeal carcinoma; and Fast Track designation to a ...

Symptom Management

Wearable Temperature Sensor May Aid in Detecting Febrile Adverse Events in Patients With Cancer

A simple, wearable temperature sensor was able to detect dangerous complications in hospitalized patients with cancer hours earlier than routine monitoring. The device, which takes readings every 2 minutes and wirelessly transmits them to the cloud, was able to quickly detect adverse events that...

Hematologic Malignancies
Symptom Management

Ruxolitinib for Glucocorticoid-Refractory or -Dependent Chronic Graft-vs-Host Disease After Allogeneic Stem Cell Transplantation

In the phase III REACH3 trial, reported in The New England Journal of Medicine, Robert Zeiser, MD, and colleagues found that ruxolitinib produced a significantly higher overall response rate vs investigator-selected control treatments in patients with glucocorticoid-refractory or -dependent chronic ...

Breast Cancer
Symptom Management

Survivors of Early-Stage Breast Cancer Face Broad Range of Symptoms and Concerns

Patients with early-stage breast cancer may be at low risk of dying of their disease, but they experience a high burden of physical and psychological symptoms long after their treatment has ended, according to data presented during the 2021 American Society of Breast Surgeons Annual Meeting.1...

Breast Cancer
Symptom Management
Pain Management

Study Examines Aromatase Inhibitor–Associated Musculoskeletal Symptoms in a Diverse Population With Early Breast Cancer

A clinical trial in a racially diverse group of postmenopausal women with early breast cancer to study severe pain in the bones, muscles, ligaments, tendons, and nerves caused by aromatase inhibitor treatment has found that the symptoms were more commonly reported in Black and Asian patients than...

Hematologic Malignancies
Symptom Management

Third-Party BK Virus–Specific Cytotoxic T-Lymphocyte Therapy for BK Virus–Associated Hemorrhagic Cystitis After Stem Cell Transplant

In a single-institution phase II trial reported in the Journal of Clinical Oncology, Olson et al found that high rates of response were achieved with third-party BK virus–specific cytotoxic T-lymphocyte therapy (BKV-CTL) in patients with BK virus–associated hemorrhagic cystitis after allogeneic...

Symptom Management

TLR4 as a Possible Therapeutic Target to Mitigate Cisplatin-Induced Hearing Loss

A research team has identified a receptor in cells that could play a role in preventing permanent hearing loss in childhood cancer survivors treated with the drug cisplatin. The researchers believe that by inhibiting the receptor, they may be able to better control otoxicity, according to findings...

Breast Cancer
Immunotherapy
Symptom Management

Incidence of Interstitial Lung Disease Related to Trastuzumab Deruxtecan-nxki in Patients With HER2-Positive Metastatic Breast Cancer

Drug-related interstitial lung disease occurred in less than 16% of patients with HER2-positive metastatic breast cancer following treatment with trastuzumab deruxtecan-nxki (T-DXd) at the approved dose of 5.4 mg/kg. In addition, the majority of these cases were classified as grade 1 or 2,...

Supportive Care
Symptom Management

Effect of Oral Chemotherapy Management Program on Capecitabine Toxicity

In a health system retrospective study reported in JCO Oncology Practice, Nhean et al found that implementation of an oral chemotherapy management program was associated with reduced rates of any-grade and severe capecitabine toxicity, less frequent toxicity-related emergency department visits and...

Hematologic Malignancies
Immunotherapy
Symptom Management

Antiviral T Cells for BK Virus–Associated Hemorrhagic Cystitis

A phase II trial has found found that BK virus (BKV)-specific T cells from healthy donors were safe and effective as an off-the-shelf therapy for BKV-associated hemorrhagic cystitis, a painful complication that is common after allogeneic stem cell transplants for patients with leukemia or lymphoma. ...

Lung Cancer
Symptom Management

Contralateral Esophagus-Sparing Radiotherapy Technique Reduces Rates of Esophagitis in Patients With Lung Cancer Receiving High-Dose Chemoradiation

In a small, single-institution phase I trial reported in JAMA Oncology, Kamran et al found that the use of a contralateral esophagus-sparing radiotherapy technique in patients receiving high-dose chemoradiation for locally advanced lung cancer was associated with no cases of grade ≥ 3 esophagitis,...

Hematologic Malignancies
Symptom Management

ROCK2 Inhibitor Belumosudil for Chronic Graft-vs-Host Disease

In a phase IIa study reported in the Journal of Clinical Oncology, Jagasia et al found that the oral ROCK2 inhibitor belumosudil produced high response rates and reduced corticosteroid use among patients with chronic graft-vs-host disease after allogeneic bone marrow or hematopoietic cell...

Skin Cancer
Immunotherapy
Symptom Management

Adverse Events in Patients With Melanoma Treated With Ipilimumab: Results of a Toxicity Monitoring Program

In a single-institution study reported in JCO Oncology Practice, Menjak et al found that a nurse-led telephone surveillance program for toxicity associated with ipilimumab in patients with metastatic melanoma led to earlier identification of toxicities and earlier intervention, with an apparent...

Breast Cancer
Symptom Management

Low-Dose Tamoxifen for Reduction of Mammographic Density in Women Undergoing Breast Cancer Screening

In the Swedish phase II KARISMA study reported in the Journal of Clinical Oncology, Eriksson et al found noninferior mammographic density reduction and reduced vasomotor symptoms following tamoxifen therapy at 2.5, 5, and 10 mg vs the standard dose of 20 mg among women undergoing breast cancer...

gynecologic cancers
symptom management

Supriya Chopra, MD, on Cervical Cancer: Reducing Late Effects of Bowel Toxicity

Supriya Chopra, MD, of Tata Memorial Centre, discusses a final analysis of the phase III PARCER trial, which showed that image-guided intensity-modulated radiotherapy is superior to conventional radiotherapy in reducing bowel toxicity in women with cervical cancer. Acute diarrhea was also reduced, with no difference in disease-related outcomes (ID# 10224).

gynecologic cancers
survivorship
symptom management

Lauren Thomaier, MD, on Predicting Chemotherapy-Induced Peripheral Neuropathy in Gynecologic Cancer Survivors

Lauren Thomaier, MD, of the University of Minnesota, discusses the genetic variants found to be associated with an increase in chemotherapy-induced neuropathy symptoms in a cohort of gynecologic cancer survivors. Combining these variants with clinical characteristics may provide an important treatment tool (ID# 10253).

Hematologic Malignancies
Supportive Care
Symptom Management

Ruxolitinib Improves Outcomes in Steroid-Refractory or Steroid-Dependent Graft-vs-Host Disease

Ruxolitinib was superior to best available therapy in achieving efficacy as determined by best overall response and duration of response, with acceptable safety in adolescents and adults with steroid-dependent or steroid-refractory chronic graft-vs-host disease effects. These findings were shown in ...

Lung Cancer
Symptom Management

FDA Approves Trilaciclib to Reduce Chemotherapy-Induced Bone Marrow Suppression in Adults Being Treated for SCLC

On February 12, the U.S. Food and Drug Administration (FDA) approved trilaciclib (Cosela) as the first therapy in its class to reduce the frequency of chemotherapy-induced bone marrow suppression in adults receiving certain types of chemotherapy for extensive-stage small cell lung cancer (SCLC)....

Leukemia
Symptom Management
COVID-19

FDA Pipeline: Breakthrough Designations in CML and for Cachexia, EUA for COVID-19

Recently, the U.S. Food and Drug Administration (FDA) issued a Breakthrough Therapy designation to asciminib for chronic myeloid leukemia (CML); a Breakthrough Device designation to an assay designed to help select patients with cachexia for treatment with an investigational therapeutic; and an...

Supportive Care
Symptom Management

ASH 2021 Guidelines for Prevention and Treatment of Venous Thromboembolism in Patients With Cancer

As reported in Blood Advances by Gary H. Lyman, MD, MPH, FASCO, FRCP, and colleagues, the American Society of Hematology (ASH) has issued evidence-based guidelines intended to assist patients, clinicians, and other health-care professionals in decisions regarding the prevention and treatment of...

Hematologic Malignancies
Supportive Care
Symptom Management

Sitagliptin Added to Tacrolimus/Sirolimus Prophylaxis Regimen for Acute Graft-vs-Host Disease After HSCT

In a phase II trial reported in The New England Journal of Medicine, Sherif S. Farag, MD, PhD, of Indiana University School of Medicine, and colleagues, found that the addition of the dipeptidyl peptidase 4 (DPP-4; CD26) inhibitor sitagliptin to tacrolimus and sirolimus prophylaxis resulted in a...

Hematologic Malignancies
Symptom Management
Supportive Care

Trading One Disease for Another: Patients With Chronic Graft-vs-Host Disease May Face Lifelong Complications

The field of allogeneic stem cell transplantation continues to improve survival for patients with previously incurable blood cancers. However, up to 50% of patients who undergo transplantation with donor cells will develop chronic graft-vs-host disease, a potentially deadly condition that can also...

Hematologic Malignancies
Supportive Care
Symptom Management

Addition of Abatacept to Acute Graft-vs-Host Disease Prophylaxis

In a phase II trial (ABA2) reported in the Journal of Clinical Oncology, Watkins et al found that the addition of T-cell costimulation blockade with abatacept to calcineurin inhibitor (CNI)/methotrexate (MTX)–based graft-vs-host disease prophylaxis resulted in reduced rates of acute graft-vs-host...

Breast Cancer
Symptom Management
Issues in Oncology

Expert Point of View: Virginia Kaklamani, MD

Press conference moderator Virginia Kaklamani, MD, of UT Health San Antonio, and Leader of the Breast Cancer Program, UT Health San Antonio MD Anderson Cancer Center, weighed in on this study. “This study compared patients’ reports with physicians’ reports about the severity of symptoms. It is a...

Breast Cancer
Symptom Management
Issues in Oncology

Severity of Patients’ Symptoms May Be Underrecognized During and After Breast Radiotherapy

Physicians may commonly underrecognize radiation-associated symptoms and their severity compared with self-reports of patients with breast cancer, according to a large study comparing patient-­reported outcomes with physician assessments of four common radiation-associated symptoms: pain, pruritus, ...

Leukemia
Immunotherapy
Symptom Management

Preemptive Tocilizumab for Cytokine-Release Syndrome in Pediatric Patients With B-Cell ALL Receiving CAR T-Cell Therapy

In a single-institution study reported in the Journal of Clinical Oncology, Kadauke et al found that risk-adapted tocilizumab reduced the expected incidence of grade 4 cytokine-release syndrome in pediatric patients receiving CD19-directed chimeric antigen receptor (CAR) T-cell...

Hematologic Malignancies
Symptom Management

Risk of Atrial Fibrillation and Associated Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation

In a single-institution study reported in the Journal of Clinical Oncology, Chang et al found that atrial fibrillation occurs in a substantial proportion of patients who have undergone allogeneic hematopoietic cell transplantation (HCT) and is associated with poor outcomes. Study Details The...

Breast Cancer
Geriatric Oncology
Symptom Management

Novel Risk Tool for Predicting Severe Toxicity in Older Patients Receiving Chemotherapy for Early-Stage Breast Cancer

As reported in the Journal of Clinical Oncology, Allison Magnuson, DO, and colleagues have developed a risk tool for predicting severe toxicity in patients aged 65 and older receiving chemotherapy for early-stage breast cancer. Study Details The prospective cohort study included 473 patients...

Hematologic Malignancies
Symptom Management

Addition of Sitagliptin to Tacrolimus/Sirolimus Prophylaxis for Acute Graft-vs-Host Disease

In a phase II trial reported in The New England Journal of Medicine, Farag et al found that the addition of the dipeptidyl peptidase 4 (DPP-4; CD26) inhibitor sitagliptin to tacrolimus and sirolimus prophylaxis resulted in a low rate of acute graft-vs-host disease among patients with hematologic...

Symptom Management

Electronic Patient Self-Reporting of Adverse Events During Cancer Chemotherapy: eRAPID System

In a single-institution phase III trial reported in the Journal of Clinical Oncology, Absolom et al found that use of the electronic patient self-reporting of adverse events: patient information and advice (eRAPID) system was associated with improvements in patient-reported outcomes vs usual care...

Prostate Cancer
Symptom Management

Study Finds Inflammation Due to Androgen-Deprivation Therapy May Contribute to Fatigue, Other Side Effects in Men With Prostate Cancer

Many patients with prostate cancer are treated with androgen-deprivation therapy. However, patients receiving androgen-deprivation therapy often experience higher levels of fatigue, depression, and cognitive impairment. In a new study published by Hoogland et al in the journal Cancer, researchers...

Symptom Management

Risk for Osteonecrosis of the Jaw After Treatment With Zoledronic Acid for Metastatic Bone Disease

In an observational cohort study reported in JAMA Oncology, Catherine H. Van Poznak, MD, FASCO, and colleagues found that the 3-year incidence of osteonecrosis of the jaw was 2.8% among patients with cancer receiving zoledronic acid for metastatic bone disease. Shorter dosing interval, fewer teeth, ...

Palliative Care
Symptom Management

Reducing the Risk of Lymphedema in Patients With Cancer

Although the exact incidence of treatment-related lymphedema among cancer survivors is unknown—most likely due to its prolonged latency period—it can be a lifelong chronic side effect that negatively impacts survivors’ quality of life. Although the condition is often linked to treatment for breast...

Gastrointestinal Cancer
Symptom Management

Initiative to Increase Referrals of Patients With Gastrointestinal Cancer to a Specialized Rehabilitation Program

In a single-institution study reported in JCO Oncology Practice, Nadler et al describe the development of an intervention at Princess Margaret Cancer Centre, Toronto, that succeeded in increasing referrals of patients with gastrointestinal cancer to a cancer rehabilitation program. As stated by the ...

Breast Cancer
Symptom Management
Issues in Oncology

SABCS 2020: Patients With Breast Cancer Undergoing Radiotherapy May Have Underrecognized Side Effects

Among patients with breast cancer treated with radiotherapy, symptoms were commonly underrecognized in reports of pain, pruritus, edema, and fatigue, with younger patients and Black patients having significantly increased odds of symptom underrecognition. These findings were reported by Reshma...

Hematologic Malignancies
Symptom Management

ASH 2020: Ruxolitinib for Steroid-Refractory/Steroid-Dependent Chronic Graft-vs-Host Disease

Ruxolitinib was superior to best available therapy in achieving efficacy as determined by overall response and duration of response, with acceptable safety in adolescents and adults with steroid-dependent or steroid-refractory chronic graft-vs-host disease. Findings from the phase III REACH3 trial...

Hematologic Malignancies
Symptom Management

ASH 2020: Study Finds Prophylactic Tranexamic Acid Has No Effect on Bleeding in Patients With Hematologic Malignancies

The clot stabilizer tranexamic acid performed no better than placebo when administered prophylactically to prevent bleeding in patients with hematologic malignancies who also received routine prophylactic platelet transfusions, according to findings presented by Terry B. Gernsheimer, MD, and...

Lymphoma
Leukemia
Hepatobiliary Cancer
Symptom Management
Lung Cancer
Immunotherapy

FDA Pipeline: Agents in DLBCL, SCLC, AML, and More

Recently, the U.S. Food and Drug Administration (FDA) has issued regulatory decisions for agents to treat diffuse large B-cell lymphoma (DLBCL), small cell lung cancer (SCLC), acute myeloid leukemia (AML), biliary tract cancer, and graft-vs-host disease. Priority Review for Loncastuximab Tesirine...

Symptom Management

Expert Point of View: Therese Marie Mulvey, MD, FASCO

Therese Marie Mulvey, MD, FASCO, Director of Quality Safety and Value at the Massachusetts General Hospital North Shore Cancer Center, Boston, told The ASCO Post that this “provocative and elegant” study underscores the importance of listening to patients. “Baseline patient-reported symptoms are...

Symptom Management

Ask Patients With Advanced Cancer About Fatigue: The Answer May Reveal Survival Odds

Fatigue could be an important baseline stratification factor for cancer treatment, according to data presented during the 2020 ASCO Quality Care Symposium.1 An analysis of four SWOG treatment trials has found an association between patient fatigue and outcomes in advanced cancer. Data from the...

Geriatric Oncology
Symptom Management

Expert Point of View: Monika K. Krzyzanowska, MD

Formal discussant of the abstract, Monika K. Krzyzanowska, MD, a medical oncologist at Princess Margaret Cancer Centre and Professor of Medicine at the University of Toronto, said this study extends the evidence base on geriatric assessment in oncology and shows that geriatric assessment should be...

Symptom Management
Geriatric Oncology

Reducing Symptomatic Toxicity Burden in Older Patients With Advanced Cancer Via Geriatric Assessment

As the number of older patients with cancer continues to rise, interventions that reduce the high rates of symptoms, toxicity, and distress in this population are urgently needed. Research presented during the 2020 ASCO Quality Care Symposium has added to the growing body of evidence supporting...

symptom management

Anne M. Barry-Weers, RN, on Decreasing Hospitalizations for Patients Receiving IV Chemotherapy

Anne M. Barry-Weers, RN, of Aurora Health Care/Aurora Cancer Care in Milwaukee, discusses strategies that helped patients with cancer to better manage their chemotherapy-related symptoms at home, thus reducing visits to the emergency department and inpatient admissions, and improving treatment costs (Abstract 11).

geriatric oncology
symptom management

Marie A. Flannery, PhD, and Eva Culakova, PhD, on Managing Symptoms in Older Adults With Advanced Cancer

Marie A. Flannery, PhD, and Eva Culakova, PhD, both of the University of Rochester, discuss a geriatric assessment tool that helped reduce symptomatic toxicities, as measured by Patient-Reported Outcomes Common Terminology Criteria for Adverse Events (Abstract 138).

Breast Cancer
Symptom Management

Can Routine Scans Help Predict Which Patients With Breast Cancer May Be at Risk for Heart Disease?

Automated analysis of the routine scans of patients with breast cancer may help to predict which women have a greater risk of developing cardiovascular disease, according to research presented by Gal et al at the 12th European Breast Cancer Conference (Abstract 7). Women who have been treated for...

Advertisement

Advertisement

Advertisement